You are here

Alnylam

After Alnylam’s solo maiden launch, here comes the tricky bit

After Alnylam’s solo maiden launch, here comes the tricky bit

EP Vantage

Flag link:

Alnylam Prices First Gene Silencing Drug At $450,000 Per Patient, But Offers Money-Back Guarantee

Alnylam Prices First Gene Silencing Drug At $450,000 Per Patient, But Offers Money-Back Guarantee

Forbes

hATTR amyloidosis

Flag link:

In first, FDA approves RNA interference drug from Alnylam

In first, FDA approves RNA interference drug from Alnylam

Biopharma Dive

hATTR amyloidosis

Flag link:

With patisiran launch in its sights, Alnylam plots a major hiring spree

With patisiran launch in its sights, Alnylam plots a major hiring spree

Fierce Pharma

Flag link:

Alnylam Pharmaceuticals Is "Launch Ready"

Alnylam Pharmaceuticals Is "Launch Ready"

Motley Fool

Flag link:

The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs

The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs

Yahoo/Benzinga

Pain Therapeutics

Vertex Pharmaceuticals

lumacaftor/ivacaftor

Flag link:

The UK's MHRA Grants Early Access to Anlylam's Patisiran

The UK's MHRA Grants Early Access to Anlylam's Patisiran

CP Wire

hATTR amyloidosis

Flag link:

The UK's MHRA Grants Early Access to Anlylam's Patisiran

hATTR amyloidosis

Flag link:

Alnylam Receives Positive CHMP Opinion for Hereditary Amyloidosis Treatment

Alnylam Receives Positive CHMP Opinion for Hereditary Amyloidosis Treatment

CP Wire

hATTR amyloidosis

Flag link:

Alnylam Receives Positive CHMP Opinion for Hereditary Amyloidosis Treatment

hATTR amyloidosis

Flag link:

Alnylam Presents Ph III results of Patisiran in Hereditary ATTR (hATTR) Amyloidosis

Alnylam Presents Ph III results of Patisiran in Hereditary ATTR (hATTR) Amyloidosis

CP Wire

hereditary ATTR amyloidosis

Flag link:

Alnylam Presents Ph III results of Patisiran in Hereditary ATTR (hATTR) Amyloidosis

hereditary ATTR amyloidosis

Flag link:

Poised to launch its first marketing effort, Alnylam makes a big leap into CNS diseases and Alzheimer’s

Poised to launch its first marketing effort, Alnylam makes a big leap into CNS diseases and Alzheimer’s

Endpoints

Alzheimer's disease

Flag link:

FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead

FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead

CP Wire

hereditary ATTR amyloidosis

Flag link:

FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead

Akcea Therapeutics

Flag link:

Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study

Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study

CP Wire

Primary Hyperoxaluria

Flag link:

Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study

Primary Hyperoxaluria

Flag link:

EU Advisory Group Backs Orphan Drug Designation for Alnylam's ALN-TTRsc02 for ATTR Amyloidosis

EU Advisory Group Backs Orphan Drug Designation for Alnylam's ALN-TTRsc02 for ATTR Amyloidosis

CP Wire

ATTR amyloidosis

Flag link:

EU Advisory Group Backs Orphan Drug Designation for Alnylam's ALN-TTRsc02 for ATTR Amyloidosis

Flag link:

Biotech companies Alnylam, Dicerna settle trade secrets case

Biotech companies Alnylam, Dicerna settle trade secrets case

Reuters

Flag link:

Pages